Literature DB >> 33415020

Humanized mouse model: a review on preclinical applications for cancer immunotherapy.

Ling Yin1, Xue-Jing Wang1, De-Xi Chen2, Xiao-Ni Liu2, Xiao-Jun Wang1.   

Abstract

Due to the refractory and partial sensitive treatments to malignant cancers, immunotherapy has increasingly become a hotspot in effective anti-tumor research. However, at present, existing animal models could not accurately describe the interaction between human tissue and tumor cells for preclinical trials. Furthermore, it is a tough obstacle to reconstitute the immune system and microenvironment in a mouse model identical to humans due to species differences. In the establishment of the humanized mouse model, the co-transplantation of human immunocytes with/without tissues and tumor cells is the key breakthrough to solve this problem. The compelling progress has been investigated in the preclinical drug test for diverse tumor types. This review mainly summarized the development of immunodeficient mice, and the construction and practicability of the humanized mouse model. Furthermore, the investigators also highlight the pros and cons, and recent progress in immunotherapy research for advanced utility of human cancer diseases. AJCR
Copyright © 2020.

Entities:  

Keywords:  Immunodeficient mice; cancer; humanized mouse model; immunotherapy

Year:  2020        PMID: 33415020      PMCID: PMC7783739     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  103 in total

1.  Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice.

Authors:  Elena Burova; Aynur Hermann; Jie Dai; Erica Ullman; Gabor Halasz; Terra Potocky; Seongwon Hong; Matt Liu; Omaira Allbritton; Amy Woodruff; Jerry Pei; Ashique Rafique; William Poueymirou; Joel Martin; Douglas MacDonald; William C Olson; Andrew Murphy; Ella Ioffe; Gavin Thurston; Markus Mohrs
Journal:  Mol Cancer Ther       Date:  2019-08-08       Impact factor: 6.261

2.  Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome.

Authors:  Hangyi Yan; Kenrick M Semple; Carlos M Gonzaléz; Kristina E Howard
Journal:  Transl Res       Date:  2019-04-22       Impact factor: 7.012

3.  Humanized NOD/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research.

Authors:  Leonard D Shultz; Todd Pearson; Marie King; Lisa Giassi; Lisa Carney; Bruce Gott; Bonnie Lyons; Aldo A Rossini; Dale L Greiner
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

4.  Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.

Authors:  Kyoung Ho Pyo; Jae Hwan Kim; Ji-Min Lee; Sung Eun Kim; Jae Seok Cho; Sun Min Lim; Byoung Chul Cho
Journal:  Lung Cancer       Date:  2018-11-27       Impact factor: 5.705

5.  Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs.

Authors:  Kawaljit Kaur; Paytsar Topchyan; Anna Karolina Kozlowska; Nick Ohanian; Jessica Chiang; Phyu Ou Maung; So-Hyun Park; Meng-Wei Ko; Changge Fang; Ichiro Nishimura; Anahid Jewett
Journal:  Oncoimmunology       Date:  2018-02-22       Impact factor: 8.110

6.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

7.  XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer.

Authors:  J J Morton; G Bird; S B Keysar; D P Astling; T R Lyons; R T Anderson; M J Glogowska; P Estes; J R Eagles; P N Le; G Gan; B McGettigan; P Fernandez; N Padilla-Just; M Varella-Garcia; J I Song; D W Bowles; P Schedin; A-C Tan; D R Roop; X-J Wang; Y Refaeli; A Jimeno
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

Review 8.  Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation.

Authors:  Sen Guo; Chu-Xia Deng
Journal:  Int J Biol Sci       Date:  2018-11-13       Impact factor: 6.580

9.  Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.

Authors:  Chun-Hui Jin; Jinxing Xia; Sarwish Rafiq; Xin Huang; Zheng Hu; Xianzheng Zhou; Renier J Brentjens; Yong-Guang Yang
Journal:  EBioMedicine       Date:  2018-12-20       Impact factor: 8.143

10.  Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1-Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice.

Authors:  Simon Danisch; Constanze Slabik; Angela Cornelius; Manuel Albanese; Takanobu Tagawa; Yen-Fu A Chen; Nicole Krönke; Britta Eiz-Vesper; Stefan Lienenklaus; Andre Bleich; Sebastian J Theobald; Andreas Schneider; Arnold Ganser; Constantin von Kaisenberg; Reinhard Zeidler; Wolfgang Hammerschmidt; Friedrich Feuerhake; Renata Stripecke
Journal:  Am J Pathol       Date:  2018-12-26       Impact factor: 4.307

View more
  13 in total

1.  Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up.

Authors:  Eva Oswald; Daniel Bug; Anne Grote; Kanstantsin Lashuk; Nassim Bouteldja; Dorothee Lenhard; Anne Löhr; Anke Behnke; Volker Knauff; Anna Edinger; Kerstin Klingner; Simone Gaedicke; Gabriele Niedermann; Dorit Merhof; Friedrich Feuerhake; Julia Schueler
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 12.469

Review 2.  Swine models for translational oncological research: an evolving landscape and regulatory considerations.

Authors:  Adeline N Boettcher; Kyle M Schachtschneider; Lawrence B Schook; Christopher K Tuggle
Journal:  Mamm Genome       Date:  2021-09-02       Impact factor: 3.224

Review 3.  Interspecies chimeras as a platform for exogenic organ production and transplantation.

Authors:  Daniel J Garry; Mary G Garry
Journal:  Exp Biol Med (Maywood)       Date:  2021-06-24

4.  miR-204-containing exosomes ameliorate GVHD-associated dry eye disease.

Authors:  Tian Zhou; Chang He; Peilong Lai; Ziqi Yang; Yan Liu; Huiyi Xu; Xiaojing Lin; Biyan Ni; Rong Ju; Wei Yi; Lingyi Liang; Duanqing Pei; Charles E Egwuagu; Xialin Liu
Journal:  Sci Adv       Date:  2022-01-12       Impact factor: 14.136

5.  Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.

Authors:  Nadine Aschmoneit; Lennart Kühl; Oliver Seifert; Roland E Kontermann
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

Review 6.  Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.

Authors:  Alessandra Ciucci; Marianna Buttarelli; Anna Fagotti; Giovanni Scambia; Daniela Gallo
Journal:  Cell Mol Life Sci       Date:  2022-06-16       Impact factor: 9.207

7.  Humanized Mouse Model as a Novel Approach in the Assessment of Human Allogeneic Responses in Organ Transplantation.

Authors:  Ashwin Ajith; Laura L Mulloy; Md Abu Musa; Valia Bravo-Egana; Daniel David Horuzsko; Imran Gani; Anatolij Horuzsko
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

Review 8.  Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies.

Authors:  Bethany Bareham; Nikitas Georgakopoulos; Alba Matas-Céspedes; Michelle Curran; Kourosh Saeb-Parsy
Journal:  Cancer Immunol Immunother       Date:  2021-04-08       Impact factor: 6.968

Review 9.  Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models.

Authors:  Xiaohui Si; Lu Xiao; Christine E Brown; Dongrui Wang
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923

10.  Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy.

Authors:  Joseph I Hoare; Bleona Osmani; Emily A O'Sullivan; Ashley Browne; Nicola Campbell; Stephen Metcalf; Francesco Nicolini; Jayeta Saxena; Sarah A Martin; Michelle Lockley
Journal:  Commun Biol       Date:  2022-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.